# **Screening Libraries**

# **Product** Data Sheet

# Fluvastatin sodium

Cat. No.: HY-14664A CAS No.: 93957-55-2 Molecular Formula: C<sub>24</sub>H<sub>25</sub>FNNaO<sub>4</sub> Molecular Weight: 433.45

HMG-CoA Reductase (HMGCR); Autophagy; Ferroptosis Target: Pathway: Metabolic Enzyme/Protease; Autophagy; Apoptosis

Storage: 4°C, sealed storage, away from moisture

\* In solvent: -80°C, 1 years; -20°C, 6 months (sealed storage, away from moisture)

## **SOLVENT & SOLUBILITY**

In Vitro

H<sub>2</sub>O: 50 mg/mL (115.35 mM; Need ultrasonic) DMSO: 50 mg/mL (115.35 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	2.3071 mL	11.5354 mL	23.0707 mL
	5 mM	0.4614 mL	2.3071 mL	4.6141 mL
	10 mM	0.2307 mL	1.1535 mL	2.3071 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (5.77 mM); Clear solution
- 2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE- $\beta$ -CD in saline) Solubility: ≥ 2.5 mg/mL (5.77 mM); Clear solution
- 3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (5.77 mM); Clear solution

# **BIOLOGICAL ACTIVITY**

Description	Fluvastatin sodium (XU 62320) is a first fully synthetic, competitive HMG-CoA reductase inhibitor with an IC <sub>50</sub> of 8 nM. Fluvastatin sodium protects vascular smooth muscle cells against oxidative stress through the Nrf2-dependent antioxidant pathway <sup>[1][2][3]</sup> .	
IC <sub>50</sub> & Target	IC50: 8 nM (HMG-CoA reductase) <sup>[1]</sup>	
In Vitro	Fluvastatin sodium (XU 62320) is a competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase (HMGCR), the enzyme that catalyzes the conversion of HMG-CoA to mevalonic acid, the rate-limiting step in cholesterol biosynthesis.	

Human hepatocellular carcinoma cell (HCC) studies indicate that Fluvastatin induces G2/M phase arrest. In the presence of Fluvastatin (XU 62320), HCC cells show a decrease of Bcl-2 and procaspase-9 expression, and an increase in Bax, cleaved caspase-3, and cytochrome c. Fluvastatin (XU 62320) is antilipemic and is used to reduce plasma cholesterol levels and prevent cardiovascular disease.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### **CUSTOMER VALIDATION**

- Chem Eng J. 1 January 2023, 138972.
- Pharmacol Res. 2023 Mar 10;106724.
- Cell Prolif. 2021 Jan;54(1):e12953.
- Front Bioeng Biotechnol. 2022 Mar 17;10:826093.
- Front Cell Dev Biol. 2020 May 28;8:404.

See more customer validations on www.MedChemExpress.com

### **REFERENCES**

[1]. Makabe S, et al. Fluvastatin protects vascular smooth muscle cells against oxidative stress through the Nrf2-dependent antioxidant pathway. Atherosclerosis. 2010 Dec;213(2):377-84.

[2]. Wu Zhang, et al. Fluvastatin, a lipophilic statin, induces apoptosis in human hepatocellular carcinoma cells through mitochondria-operated pathway. Indian J Exp Biol. 2010 Dec;48(12):1167-74.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

Page 2 of 2 www.MedChemExpress.com